Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics | $11.27 | $7.01 | 164.55% | 33M | $40M | $3.50$16.25 |
| ARTV | Artiva Biotherapeutics | $6.43 | $3.13 | 94.85% | 403.2K | $81M | $1.47$11.55 |
| ASTI | Ascent Solar Technologies | $4.28 | $1.16 | 37.26% | 3.6M | $11M | $1.10$4.60 |
| KXIN | Kaixin | $4.38 | $1.06 | 31.93% | 1.2M | $20M | $2.94$75.00 |
| KYTX | Kyverna Therapeutics | $11.08 | $2.30 | 26.21% | 16.9M | $385M | $1.78$13.67 |
| IMNM | Immunome | $23.56 | $3.99 | 20.36% | 9.5M | $1.8B | $5.15$25.30 |
| CPIX | Cumberland Pharmaceuticals | $3.04 | $0.51 | 20.16% | 457K | $38M | $1.85$7.25 |
| IONZ | Tidal Trust II - Defiance Daily Target 2x Short Ionq ETF | $25.53 | $4.21 | 19.75% | 942.8K | - | $12.48$137.71 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $10.00 | $1.60 | 19.06% | 952.7K | - | $7.50$25.51 |
| RENT | Rent The Runway | $7.80 | $1.15 | 17.29% | 378.5K | $222M | $3.31$9.07 |
Related Articles
Featured Article
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Leo Miller|Aug 29, 2024
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Alex Carchidi|Feb 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Alex Carchidi|Jul 1, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Advertisement
Is It Too Late to Buy Rent the Runway Stock?
Leo Sun|Dec 10, 2022
The apparel rental marketplace could be on the cusp of a comeback.
This Surprising Sector Is Sinking the Nasdaq Thursday
Dan Caplinger|Sep 1, 2022
It's not all about technology stocks.
Buying This IPO Could Be a Big Mistake
Asit Sharma, CPA|Nov 9, 2021
Rent the Runway is looking to invent a cloud-based wardrobe for fashionistas across the world, but its business is already looking shabby.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Keith Speights|Jul 29, 2021
FDA approval of roxadustat seems unlikely.
Why Five Below, Sportsman's Warehouse, and Duluth Holdings All Moved by 10% Today
Reuben Gregg Brewer|Sep 3, 2020
Three retailers are putting up large early morning moves, two up and one down. Here's what you need to know.
FibroGen's Anemia Drug Goes to FDA for Review
Eric Volkman|Feb 12, 2020
A decision on Roxadustat should arrive by Dec. 20.
FibroGen Appoints Enrique Conterno as Its New CEO
Brian Orelli, PhD|Jan 6, 2020
The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=384&op=resize)